Episode Details
Back to EpisodesWhat is the risk of rhabdomyolysis in patients taking both SGLT2 inhibitors and statins?
Episode 439
Published 1 year, 9 months ago
Description
In this podcast, a study from Ontario revealed that SGLT2 inhibitors, when combined with statins, were associated with a 25% lower risk of rhabdomyolysis compared to DPP4 inhibitors. A phase I trial at Washington University demonstrated promising outcomes for a neoantigen DNA vaccine aimed at preventing recurrence in triple-negative breast cancer (TNBC). Finally, intensive systolic blood pressure control in Chinese patients with type 2 diabetes and elevated cardiovascular risk significantly reduced major cardiovascular events compared to standard care.